BTK
Les inhibiteurs de la tyrosine kinase de Bruton (BTK) sont des composés qui ciblent spécifiquement et inhibent la BTK, une enzyme cruciale impliquée dans la signalisation du récepteur des cellules B et la régulation de l'angiogenèse. La BTK joue un rôle significatif dans la prolifération et la survie des cellules cancéreuses, en particulier dans les malignités hématologiques. En inhibant la BTK, ces composés peuvent perturber l'angiogenèse et la croissance tumorale, ce qui les rend précieux en thérapie anticancéreuse. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de la BTK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
166 produits trouvés pour "BTK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BLK-IN-2
CAS :BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。
Formule :C39H41N9O3Couleur et forme :SolidMasse moléculaire :683.8JAK3/BTK-IN-6
CAS :JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.Formule :C21H17BF3N5O3Couleur et forme :SolidMasse moléculaire :455.2BTK-IN-22
CAS :BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.Formule :C26H26N6O2Couleur et forme :SolidMasse moléculaire :454.52GDC-0834 Racemate
CAS :GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitorFormule :C33H36N6O3SCouleur et forme :SolidMasse moléculaire :596.74HZ-A-005
CAS :HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.Formule :C25H23ClN6O2Couleur et forme :SolidMasse moléculaire :474.94BI-1622
CAS :BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.Formule :C26H24N10O2Couleur et forme :SolidMasse moléculaire :508.53BLK degrader 1
CAS :BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.Formule :C32H25F3N6O2Degré de pureté :99.22% - 99.24%Couleur et forme :SolidMasse moléculaire :582.58JS25
CAS :JS25, a selective BTK inhibitor, inactivates it with a 5.8 nM IC50, halts cancer cell growth, induces death, and aids against lymphoma.Formule :C29H24N4O4SCouleur et forme :SolidMasse moléculaire :524.59BTK-IN-23
CAS :BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.Formule :C27H28N6O2Couleur et forme :SolidMasse moléculaire :468.55JNJ-64264681
CAS :JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK).Formule :C27H30N6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :518.63Ibrutinib-MPEA
CAS :Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Formule :C32H39N9O2Couleur et forme :SolidMasse moléculaire :581.71CGI560
CAS :CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.Formule :C29H27N5OCouleur et forme :SolidMasse moléculaire :461.56SB-633825
CAS :SB-633825 can inhibit cancer cell growth and angiogenesis.Formule :C28H25N3O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :483.58Sunvozertinib
CAS :Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.Formule :C29H35ClFN7O3Degré de pureté :98.11% - 99.63%Couleur et forme :SolidMasse moléculaire :584.08Ref: TM-T64124
1mg34,00€5mg60,00€10mg85,00€25mg124,00€50mg200,00€100mg353,00€500mg1.314,00€1mL*10mM (DMSO)150,00€Tilfrinib
CAS :Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.Formule :C17H13N3ODegré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :275.3Ref: TM-T17098
1mg43,00€2mg56,00€5mg93,00€10mg130,00€25mg243,00€50mg439,00€100mg645,00€500mg1.333,00€1mL*10mM (DMSO)93,00€(±)-Zanubrutinib
CAS :(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,Formule :C27H29N5O3Degré de pureté :99.09%Couleur et forme :SolidMasse moléculaire :471.55Ref: TM-TQ0039
1mg47,00€5mg92,00€10mg145,00€25mg256,00€50mg409,00€100mg587,00€500mg1.215,00€1mL*10mM (DMSO)101,00€CHMFL-EGFR-202
CAS :CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).Formule :C25H24ClN7O2Degré de pureté :99.66%Couleur et forme :SolidMasse moléculaire :489.96Ref: TM-T10802
1mg109,00€2mg163,00€5mg241,00€10mg355,00€25mg532,00€50mg745,00€100mg1.018,00€1mL*10mM (DMSO)289,00€Larotinib
CAS :Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.Formule :C24H26ClFN4O4Degré de pureté :99.73%Couleur et forme :SolidMasse moléculaire :488.94NX-2127
CAS :NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferativeFormule :C39H45N9O5Degré de pureté :99.07%Couleur et forme :SolidMasse moléculaire :719.83(R)-Zanubrutinib
CAS :(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).Formule :C27H29N5O3Degré de pureté :99.55%Couleur et forme :SolidMasse moléculaire :471.55Ref: TM-T13447
1mg37,00€5mg80,00€10mg133,00€25mg215,00€50mg323,00€100mg442,00€200mg615,00€1mL*10mM (DMSO)85,00€Edralbrutinib
CAS :Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood andFormule :C26H21F2N5O3Degré de pureté :99.41%Couleur et forme :SolidMasse moléculaire :489.47BTK-IN-11
CAS :BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)Formule :C26H22ClN5O3Couleur et forme :SolidMasse moléculaire :487.94BMX-IN-1
CAS :BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosineFormule :C29H24N4O4SDegré de pureté :98.38%Couleur et forme :SolidMasse moléculaire :524.59DDa-1
CAS :DDa-1 is a potent (kinase degrader) [1].Formule :C60H77Cl2N13O3SCouleur et forme :SoildMasse moléculaire :1131.31BTK-IN-17
BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.Formule :C26H23N7O2Couleur et forme :SolidMasse moléculaire :465.51BTK-IN-18
CAS :BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.Formule :C20H22Cl2N6OCouleur et forme :SolidMasse moléculaire :433.33PF-303
CAS :PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.Formule :C22H21ClN6O2Couleur et forme :SolidMasse moléculaire :436.89(Rac)-PF-06250112
CAS :(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.Formule :C22H20F2N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :438.43BTK-IN-19
CAS :BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .Formule :C21H22Cl2N6OCouleur et forme :SolidMasse moléculaire :445.35Cinsebrutinib
CAS :Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.Formule :C22H26FN3O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :383.46BTK inhibitor 13
CAS :BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).Formule :C29H26FN5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :511.55BTK inhibitor 20
CAS :BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .Formule :C37H42N8O4Couleur et forme :SolidMasse moléculaire :662.78PF-06250112
CAS :PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.Formule :C22H20F2N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :438.43Pirtobrutinib
CAS :Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.Formule :C22H21F4N5O3Degré de pureté :99.76% - 99.94%Couleur et forme :SolidMasse moléculaire :479.43Ref: TM-T36287
1mg37,00€5mg79,00€10mg126,00€25mg283,00€50mg434,00€100mg638,00€500mg1.359,00€1mL*10mM (DMSO)84,00€BTK inhibitor 1
CAS :BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.
Formule :C24H23FN8O2Degré de pureté :98.24% - 98.91%Couleur et forme :SolidMasse moléculaire :474.49BGB-8035
CAS :BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.Formule :C24H31N5O4Degré de pureté :96.74%Couleur et forme :SolidMasse moléculaire :453.53BMS-935177
CAS :BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formule :C31H26N4O3Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :502.56TAK-020
CAS :TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Formule :C18H17N5O3Degré de pureté :98.66%Couleur et forme :SolidMasse moléculaire :351.36Ref: TM-T9529
1mg138,00€5mg334,00€10mg597,00€25mg1.234,00€50mg1.908,00€100mg2.952,00€1mL*10mM (DMSO)358,00€BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Formule :C23H22FN5O3Couleur et forme :SolidMasse moléculaire :435.45BTK inhibitor 18
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.Formule :C29H25N5O4S2Couleur et forme :SolidMasse moléculaire :571.67GNE-431
CAS :GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Formule :C30H32N10O2Couleur et forme :SolidMasse moléculaire :564.64JAK3/BTK-IN-7
CAS :JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].Formule :C29H30N8O4Couleur et forme :SolidMasse moléculaire :554.6JAK3/BTK-IN-3
CAS :JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.Formule :C22H28N8OCouleur et forme :SolidMasse moléculaire :420.51Brefeldin A 4-O-nicotinate
CAS :Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins with an IC50 value of 0.22 μM for T24 cell proliferation. It also suppresses T24 cell migration and colony formation in a dose-dependent manner, induces G1 phase arrest, and triggers apoptosis. By targeting BMX proteins, it inhibits the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, while also inhibiting Arf1 proteins to eliminate bladder cancer stem cells and activate antitumor immunity, thus exhibiting anticancer activity. Brefeldin A 4-O-nicotinate is applicable in research related to bladder cancer.Formule :C22H27NO5Couleur et forme :SolidMasse moléculaire :385.453BTK-IN-16
CAS :BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.Formule :C15H14N4O2Degré de pureté :99.04%Couleur et forme :SoildMasse moléculaire :282.3BIIB129
CAS :BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.Formule :C19H22N6O2Degré de pureté :98.56%Couleur et forme :SolidMasse moléculaire :366.42JAK3/BTK-IN-4
CAS :JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formule :C21H25ClN8OCouleur et forme :SolidMasse moléculaire :440.93WS-11
CAS :WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Formule :C26H22FN9O2Couleur et forme :SolidMasse moléculaire :511.51BTK-IN-38
CAS :BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.Formule :C27H26F2N4O2Couleur et forme :SolidMasse moléculaire :476.52BMS-986143
CAS :BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formule :C31H24Cl2N4O4Couleur et forme :SolidMasse moléculaire :587.45UBX-382
CAS :UBX-382 is an orally administered proteolysis-targeting chimera (PROTAC) designed to target BTK and disrupt B-cell receptor signaling. It demonstrates enhanced degradation of both wild-type and mutant BTK proteins, exhibiting anti-cancer effects in murine xenograft models using TMD-8 cells [1].Formule :C42H44N10O4Couleur et forme :SolidMasse moléculaire :752.86BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formule :C28H24FN5O2Couleur et forme :SolidMasse moléculaire :481.52BTK-IN-32
CAS :BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Formule :C35H35ClN4O3SCouleur et forme :SolidMasse moléculaire :627.2RET-IN-14
CAS :RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.Formule :C24H23FN8O4Couleur et forme :SolidMasse moléculaire :506.49G-744
CAS :G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).Formule :C29H29N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :527.64TQ-3959
CAS :TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Formule :C40H47N11O5Couleur et forme :SolidMasse moléculaire :761.87(Rac)-Ibrutinib alkyne
CAS :(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Formule :C25H22N6O2Couleur et forme :SolidMasse moléculaire :438.48BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Formule :C26H36N6O3Couleur et forme :SolidMasse moléculaire :480.6BTK-IN-34
CAS :BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Formule :C22H29N3O4SCouleur et forme :SolidMasse moléculaire :431.55HDHD4-IN-1
CAS :HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Formule :C12H22NO11PCouleur et forme :SolidMasse moléculaire :387.28BTK-IN-10
CAS :BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Formule :C25H24F2N4O2Couleur et forme :SolidMasse moléculaire :450.48Ibrutinib Racemate
CAS :Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formule :C25H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.5Dihydrodiol-Ibrutinib
CAS :PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formule :C25H26N6O4Couleur et forme :SolidMasse moléculaire :474.521JDB175
CAS :JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.
Formule :C26H21F3N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :478.47BTK-IN-25
CAS :BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].
Formule :C28H27F2N3O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :523.53BTK-IN-27
CAS :BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.
Formule :C31H35N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :537.66
